Clearmind Medicine Inc. — Form 6-K Summary
Reporting period: September 2026. The filing, dated September 30, 2026, reports a planned reverse share split; it does not provide financial statements or operating results.
Business context and share consolidation
The company will consolidate its common shares at a ratio of 1-for-8: each eight common shares will become one common share. Trading on the Nasdaq Capital Market on a post-split basis is scheduled to begin Monday, October 5, 2026.
- Issued and outstanding shares are expected to change from 4,059,227 to 507,404, subject to adjustments for fractional shares.
- No fractional shares will be issued; fractional entitlements will be rounded up to the nearest whole share.
- The authorized share capital will remain unchanged.
- Outstanding options and warrants will receive proportionate adjustments to exercise prices and the number of shares issuable.
- New CUSIP: 185053709.
Financial metrics and changes versus prior period
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or guidance figures. It provides no comparable-period financial results. The disclosed change is the planned 1-for-8 share consolidation.
Outlook, risks, and other items
The filing does not provide management commentary, business outlook, or discussion of risks or contingencies. It states that the report is incorporated by reference into specified existing Form F-3 and Form S-8 registration statements, to the extent not superseded by later filings.
Key facts for investors to verify
- Confirm the split’s implementation and the first post-split trading date of October 5, 2026.
- Verify the final outstanding share count, including treatment of fractional shares.
- Confirm the new CUSIP and the adjustments to outstanding options and warrants.